The long-term goal of the cervical cancer SPORE at Johns Hopkins is to reduce the incidence, morbidity, and mortality related to cervical cancers via rapid translation of scientific advance. SPORE projects are translational in nature and aim to develop intervention strategies for the prevention and treatment for cervical cancer.
Project 1: Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer globally.
Project 2: Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL
Project 3: Electroporation delivery of pNGVL4aCRTE6E7L2 DNA for treatment of HPV16+ HSIL patients
Project 4: A randomized, open label clinical trial to assess the safety, feasibility, and immunogenicity of adjuvant PVX7 immunotherapy regimens in advanced cervical cancer patients.
The organization and timetable of the SPORE projects are summarized in the charts below. Table 1 indicates the research areas addressed by each SPORE project. A translational timeline for each project is shown in Table 2, demonstrating the translational scope of each project along a research/clinical progress continuum.
